Navigation Links
Yale researchers identify targets for immunotherapy in early-stage breast cancer
Date:7/18/2014

July 17, 2014, New Haven, CT Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the amount of PD-L1 (programmed death ligand 1) mRNA in routine formalin-fixed cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials. The findings were published in the Journal of Clinical Cancer Research in May.

PD-L1 is a protein that plays an important role in suppressing immune response, and in cancer, it may allow tumors to evade immune attack. The study demonstrated that about 60 percent of early-stage breast cancers have PD-L1 expression, and a subset of these cancers also have large numbers of tumor infiltrating lymphocytes. High levels of lymphocytes and PD-L1 predicted for better survival, suggesting a beneficial role for the immune system in at least partially controlling these cancers.

"This is exciting because these findings provide the rationale to test PD-L1 targeted therapies in breast cancer with the hope of further improving cure rates in early stage breast cancer," said Lajos Pusztai, MD, DPhil, professor of Medical Oncology and chief of Breast Medical Oncology at Smilow Cancer Hospital, Yale Cancer Center, and an author on the study. "Patients with many tumor infiltrating lymphocytes and high PD-L1 expression may be the ideal candidates for these therapies."

The in situ mRNA detection method used in the study, eliminates many of the technical problems that older immunohistochemistry assays had, Pusztai added.


'/>"/>

Contact: Vicky Agnew
vicky.agnew@yale.edu
203-785-7001
Yale University
Source:Eurekalert

Page: 1

Related biology news :

1. CNIO researchers discover a gene that links stem cells, aging and cancer
2. Duck migration study reveals importance of conserving wetlands, MU researchers find
3. Researchers advance understanding in immune response to infectious disease
4. Researchers find organic pollutants not factor in turtle tumor disease
5. Largest International Meeting for the Study of Reproductive Biology Attracts Researchers from 36 Countries in Grand Rapids, Michigan
6. Little too late: Researchers identify disease that may have plagued 700-year-old skeleton
7. Researchers declassify dinosaurs as being the great-great-grandparents of birds
8. IPCC must consider alternate policy views, researchers say
9. Science and cookies: Researchers tap into citizen science to shed light on ant diversity
10. Researchers receive $12.6 million NIH grant to study genetics of Alzheimers
11. Researchers uncover new knowledge about our intestines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a ... has appointed Steve Gerber to the new role ... be responsible for leading development of mobile platforms and wearable ... of success and innovation in the semiconductor industry to his ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... team led by St. Jude Children,s Research Hospital scientists ... the childhood eye tumor retinoblastoma. Their work also settles ... are as scrambled as the developmental pathways at work ... a particular type of cell, researchers showed that retinoblastoma ...
... recent study suggests that parasites in fish, including threatened species ... fish health than has been assumed, and could be one ... changes cause salmon mortality. It,s not just the presence ... but their numbers that can build up over years or ...
... Extinction is a focal issue among scientists, policy makers ... are thought to have disappeared are rediscovered. Yet, these ... from the National University of Singapore (NUS), University of ... 122 years, at least 351 species which are thought ...
Cached Biology News:Childhood eye tumor made up of hybrid cells with jumbled development 2Childhood eye tumor made up of hybrid cells with jumbled development 3Parasite loads an underlying cause of salmon mortality, linked to land use changes 2Rediscovery of disappeared species: Truly back from the brink? 2
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, 2015 /PRNewswire/ ... a leader in synthetic biology, today announced it has ... (OSF), the pioneering agricultural company behind the ... apple. Through the acquisition, Intrexon expands its food programs ... and convenient for consumers while providing economic benefit throughout ...
(Date:2/27/2015)... , Feb. 27, 2015 A paper ... NCATS rare-diseases portfolio " in Science Translational ... financing technique to reduce the risk associated with ... potentially unlock new levels of funding for developing ... of a unique collaboration between scientists at the ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is ... of BNC105 in patients with metastatic renal cancer at ... Florida . The data will be presented by ... Hope Comprehensive Cancer Center in California ... new data identifies Ferritin and IL-8 as two baseline ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... on August 21 and Roth Capital,s 2007 New York ... ... Strategic Diagnostics,Inc. (Nasdaq: SDIX ) -- a leading ... water, agricultural, environmental and,life science applications, announced today that its ...
... BioMaxx Systems Inc. (Other,OTC: BMXSF), is pleased ... with,Alcofuel Technologies Ltd., for the provision of the ... to the engagement,letter, Alcofuel Technologies has agreed, subject ... to design and manufacture a small,scale ethanol micro-refinery ...
... Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... product candidates for the treatment,of cancer and ... Food and,Drug Administration (FDA) has granted fast ... is currently being investigated in a,pivotal Phase ...
Cached Biology Technology:Strategic Diagnostics to Present at Two Upcoming Investor Conferences 2Strategic Diagnostics to Present at Two Upcoming Investor Conferences 3Strategic Diagnostics to Present at Two Upcoming Investor Conferences 4Strategic Diagnostics to Present at Two Upcoming Investor Conferences 5BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3
... Kit Includes: Sufficient library for 10 ... 10^9 independent sequences, -28 gIII Sequencing ... sequencing, -96 gIII Sequencing Primer (100 ... E. coli strain ER2738, Control target ...
...
... library screening, optimal siRNA transfection ... verified for each cell type ... Transfection Optimization Kit, which was ... conditions in 96 well plates, ...
Applications: Western blotting ...
Biology Products: